John’s practice includes the representation of a range of start-up and late-stage biotechnology and pharmaceutical companies, both private and public. He has extensive experience in venture capital financing, private placements, mergers and acquisitions, public offerings, and general corporate matters. In addition, he specializes in technology licensing transactions and in the structuring and negotiation of sponsored research and other collaborations, strategic alliances, and joint ventures.
John has represented a number of biotechnology clients in their early- and late-stage financing transactions. Recently, he negotiated and closed a $75 million equity financing transaction, which was the highest-grossing, self-managed private placement ever consummated within the biotechnology industry.
John has also been involved in a number of complex collaboration and joint venture transactions with biotechnology and pharmaceutical companies, including a collaboration/co-development transaction valued at approximately $1.5 billion, which remains the largest collaboration (in terms of aggregate value) between a biotechnology and pharmaceutical company completed to date.
In addition, John has served as both company counsel and underwriter’s counsel on initial public offerings, follow-on offerings, and PIPE financing transactions involving a number of biotechnology and medical device companies.
Articles in the National Law Review database by John J. Cheney